Patent 12377204
Litigation summary
Past and pending lawsuits — plaintiffs, defendants, jurisdictions, outcomes, and notable rulings.
Active provider: Google · gemini-2.5-pro
PTAB activity (1)
AIA trial proceedings — IPR, PGR, CBM — filed at the USPTO Patent Trial and Appeal Board against this patent. Sourced directly from the PTAB Trial API.
- PGR2026-00006PGRfiled Oct 21, 2025vs. Terumo BCT, IncDiscretionary Denial
Cached for 24 hours. Status strings are sourced verbatim from the PTAB API; the colored badge is our heuristic classification.
Cases on file (2)
Group view →Specific litigation cases in our database that name US patent 12377204. The free-form analysis below may also discuss cases beyond this list.
- Haemonetics Corporation v. Terumo BCT, Inc.filed May 5, 20251:25-cv-01409United States District Court for the District of ColoradoOngoing
Defendants: Terumo BCT, Inc.
Other patents asserted: 10980926, 10758652, 10792416, 10980934, 11738124, 12171916, 12186474, 12324873
- Haemonetics Corp. v. Terumo BCT, Inc.filed May 5, 20251:25-cv-01409-RMR-SBPU.S. District Court for the District of Coloradoactive
Defendants: Terumo BCT, Inc.
Litigation summary
Past and pending lawsuits — plaintiffs, defendants, jurisdictions, outcomes, and notable rulings.
Litigation Involving US Patent 12,377,204
As of April 26, 2026, US Patent 12,377,204 is involved in at least one known litigation. Details of the case are provided below.
Haemonetics Corp. v. Terumo BCT, Inc.
- Plaintiff: Haemonetics Corp.
- Defendant: Terumo BCT, Inc.
- Jurisdiction: U.S. District Court for the District of Colorado.
- Case Number: 1:25-cv-01409-RMR-SBP.
- Filing Date of Action: The initial complaint was filed on May 5, 2025. However, US Patent 12,377,204 was specifically added to the lawsuit in the Second Amended Complaint on August 12, 2025.
- Outcome or Current Status: The case is currently active. Haemonetics alleges that Terumo BCT infringes upon the asserted patents, including the '204 patent, which cover systems for collecting plasma based on a donor's specific characteristics. Haemonetics is seeking injunctive relief and compensatory damages. Terumo BCT denies the allegations and, as of September 2, 2025, had filed a partial motion to dismiss the complaint, arguing that the asserted patents are invalid. Terumo BCT has also initiated inter partes review (IPR) and post-grant review (PGR) proceedings with the U.S. Patent and Trademark Office challenging the validity of asserted patents. A motion to stay the district court litigation pending the resolution of these PTAB challenges was filed by Terumo on November 7, 2025, and is pending. A scheduling order indicates that claim construction is anticipated to begin in early 2026.
Generated 5/13/2026, 12:23:52 AM